Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374049 | 1.00 | ESR2 (0.41) | ESR2LMNAMEN1MAPTTHRB | |
| SCHEMBL27889889 | 0.89 | ESR1 (0.39) | ESR2LMNAMEN1KMT2AESR1 | |
| SCHEMBL27889892 | 0.81 | ESR2 (0.41) | ESR2MEN1MAPTKMT2AESR1 | |
| SCHEMBL5030707 | 0.77 | MRGPRX2 (0.40) | OPRM1OPRD1OPRK1 | |
| SCHEMBL7521370 | 0.77 | CYP19A1 (0.38) | LMNADRD1ALDH1A1 | |
| SCHEMBL11278569 | 0.71 | LMNA (0.38) | LMNAMEN1MAPTTHRBKMT2A | |
| SCHEMBL11282973 | 0.71 | LMNA (0.38) | ESR2LMNAMEN1MAPTTHRB | |
| SCHEMBL352510 | 0.71 | LMNA (0.47) | ESR2LMNAMEN1MAPTTHRB | |
| SCHEMBL30497725 | 0.71 | LMNA (0.47) | ESR2LMNAMEN1MAPTTHRB | |
| SCHEMBL5706922 | 0.69 | MRGPRX2 (0.49) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132240-A1 | LINEAR BLOCK COPOLYMER AND CURABLE THERMOSETTING COMPOSITION COMPRISING THE LINEAR BLOCK COPOLYMER | SHPP GLOBAL TECH B V (NL) | 2026-05-14 | — | — | US | disclosed |
| EP-3636692-B1 | POLY(ARYLENE ETHER) COPOLYMER | SHPP GLOBAL TECH BV (NL) | 2026-04-29 | — | — | EP | disclosed |
| US-20260071103-A1 | Anionic Curable Compositions | DESIGNER MOLECULES INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071104-A1 | Anionic Curable Compositions | DESIGNER MOLECULES INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12503593-B2 | Curable thermosetting composition including poly(arylene ether) copolymer | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2025-12-23 | — | — | US | disclosed |
| EP-3919545-B1 | CURABLE THERMOSETTING COMPOSITION INCLUDING POLY(ARYLENE ETHER) COPOLYMER | SHPP GLOBAL TECH BV (NL) | 2025-10-22 | — | — | EP | disclosed |
| EP-3885392-B1 | FUNCTIONALIZED POLY(ARYLENE ETHER) COPOLYMER, METHOD OF MAKING AND ARTICLES OBTAINED THEREFROM | SHPP GLOBAL TECH BV (NL) | 2025-07-02 | — | — | EP | disclosed |
| US-20250197542-A1 | COPOLYMERS DERIVED FROM DICYCLOPENTADIENE | SHPP GLOBAL TECH BV (NL) | 2025-06-19 | — | — | US | disclosed |
| US-20250122328-A1 | COPOLYMERS DERIVED FROM DICYCLOPENTADIENE | SHPP GLOBAL TECNOLOGIES B V (NL) | 2025-04-17 | — | — | US | disclosed |
| WO-2025058025-A1 | RESIN COMPOSITION, CURED ARTICLE, PREPREG, METAL-FOIL-CLAD LAMINATE BOARD, RESIN COMPOSITE SHEET, PRINTED CIRCUIT BOARD, AND SEMICONDUCTOR DEVICE | 三菱瓦斯化学株式会社 | 2025-03-20 | — | — | WO | disclosed |
| WO-2008089314-A1 | FLAME RETARDANT POLY (ARLENE ETHER) COMPOSITIONS AND ARTICLES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171817-A1 | POLY(ARYLENE ETHER) COMPOSITIONS AND ARTICLES | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2008-07-17 | — | — | US | disclosed |
| EP-1940936-A1 | POLYMER COMPOSITION, METHOD, AND ARTICLE | General Electric Company (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008036454-A1 | POLY (ARYLENE ETHER) COPOLYMER | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007044489-A1 | FLAME RETARDANT COMPOSITION AND METHOD | GENERAL ELECTRIC COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044294-A1 | POLYMER COMPOSITION, METHOD, AND ARTICLE | GENERAL ELECTRIC COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044312-A1 | POLY(ARYLENE ETHER) COMPOSITION, METHOD, AND ARTICLE | GENERAL ELECTRIC COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070080330-A1 | Flame retardant composition and method | CITIBANK, N.A., AS COLLATERAL AGENT | 2007-04-12 | — | — | US | disclosed |
| US-20070082986-A1 | Polymer composition, method, and article | SABIC GLOBAL TECHNOLOGIES IP B.V. (NL) | 2007-04-12 | — | — | US | disclosed |
| US-20070082987-A1 | Poly(arylene ether) composition, method, and article | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071104-A1 | Anionic Curable Compositions | VCL, ITGA8, GABRE | ESR2 1403/4885LMNA 125/4885MEN1 613/4885 |
| US-20260071103-A1 | Anionic Curable Compositions | CDH1, ESD, SETD2 | ESR2 1338/4885LMNA 494/4885MEN1 603/4885 |
| US-20260132240-A1 | LINEAR BLOCK COPOLYMER AND CURABLE THERMOSETTING COMPOSITION COMPRISING THE LINEAR BLOCK COPOLYMER | CBLB, UBE4A, PSMD14 | ESR2 1490/4885LMNA 2297/4885MEN1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.